Cover Image
市場調查報告書

細胞毒性T淋巴球蛋白質4 (CTLA-4,CD152) :開發中產品分析

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363120
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
Back to Top
細胞毒性T淋巴球蛋白質4 (CTLA-4,CD152) :開發中產品分析 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 112 Pages
簡介

本報告提供細胞毒性T淋巴球蛋白質4 (CTLA-4,CD152)的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Aduro BioTech, Inc.
  • Agenus, Inc.
  • Alligator Bioscience AB
  • AlphaMab Co., Ltd
  • CytomX Therapeutics, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • JHL Biotech, Inc.
  • Lytix Biopharma AS
  • Novartis AG
  • OncoImmune, Inc.
  • Pfizer Inc.
  • Premier Biomedical Inc.
  • PsiOxus Therapeutics Limited
  • Sutro Biopharma, Inc.

藥物簡介

暫停的計劃

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0599TDB

Summary

Global Markets Direct's, 'Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2016', provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted pipeline therapeutics.

The report provides comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
  • The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Overview
  • Therapeutics Development
    • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Stage of Development
    • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Therapy Area
    • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Indication
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Companies
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Products under Development by Universities/Institutes
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development
    • Aduro BioTech, Inc.
    • Agenus, Inc.
    • Alligator Bioscience AB
    • AlphaMab Co., Ltd
    • Bristol-Myers Squibb Company
    • Cold Genesys, Inc.
    • CytomX Therapeutics, Inc.
    • Immunocore Limited
    • JHL Biotech, Inc.
    • Lytix Biopharma AS
    • MedImmune, LLC
    • Novartis AG
    • OncoImmune, Inc.
    • Premier Biomedical Inc
    • PsiOxus Therapeutics Limited
    • Sutro Biopharma, Inc.
    • Theravectys SA
    • Tikcro Technologies, Ltd.
    • Xencor, Inc.
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles
    • AGEN-1884 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGEN-2041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit CTLA4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATOR-1015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic to Antagonize CTLA4 for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-0070IT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-0161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + IMCgp-100 + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ipilimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JMW-3B3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KN-044 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LTX-315 + Anti-CTLA4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-0562 + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-3617 + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit CTLA-4 for Metastatic Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CTLA-4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CTLA4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONC-392 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oncolytic Viruses to Antagonize CTLA4 for Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SNCA-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XmAb-20717 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Projects
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Featured News & Press Releases
    • Oct 08, 2016: Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study
    • Sep 06, 2016: Mesothelioma Treatment Center at Baylor St. Luke's launches clinical trial of cancer combination therapy
    • Jul 27, 2016: Combining Ipilimumab with local treatments improved survival for patients with melanoma
    • Jul 13, 2016: Immunotherapy benefits relapsed stem cell transplant recipients
    • Apr 27, 2016: Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors
    • Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate AGEN2041 at the American Association for Cancer Research (AACR) 2016 Annual Meeting
    • Feb 29, 2016: AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma
    • Feb 17, 2016: Immune-targeting drug combo shows promise for lung cancer patients, says Moffitt
    • Feb 08, 2016: Astrazeneca'S Combination of Durvalumab with Tremelimumab Shows Clinical Activity in Non-Small Cell Lung Cancer Irrespective Of PD-L1 Status
    • Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-CTLA-4 Antibody
    • Oct 28, 2015: Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Treatment for Fully Resected Stage III Melanoma
    • Oct 19, 2015: Cold Genesys Announces FDA Acceptance of a Phase I/II Clinical Trial Using CG0070 Plus an Anti-CTLA-4 Checkpoint Inhibitor as a Neo-Adjuvant Immunotherapy for Muscle Invasive Bladder Cancer
    • Jun 02, 2015: AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015
    • May 31, 2015: Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo + Yervoy Regimen or Opdivo Monotherapy vs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Melanoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Aduro BioTech, Inc., H2 2016
  • Pipeline by Agenus, Inc., H2 2016
  • Pipeline by Alligator Bioscience AB, H2 2016
  • Pipeline by AlphaMab Co., Ltd, H2 2016
  • Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Pipeline by Cold Genesys, Inc., H2 2016
  • Pipeline by CytomX Therapeutics, Inc., H2 2016
  • Pipeline by Immunocore Limited, H2 2016
  • Pipeline by JHL Biotech, Inc., H2 2016
  • Pipeline by Lytix Biopharma AS, H2 2016
  • Pipeline by MedImmune, LLC, H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by OncoImmune, Inc., H2 2016
  • Pipeline by Premier Biomedical Inc, H2 2016
  • Pipeline by PsiOxus Therapeutics Limited, H2 2016
  • Pipeline by Sutro Biopharma, Inc., H2 2016
  • Pipeline by Theravectys SA, H2 2016
  • Pipeline by Tikcro Technologies, Ltd., H2 2016
  • Pipeline by Xencor, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top